Shots:
- Bain Capital and Cinven to acquire Lonza’s specialty ingredients business and operations for an enterprise value of $4.7B. The transaction is expected to close in H2’21
- The divestiture will allow Lonza to refocus its business as a pure-play partner to the healthcare industry
- Lonza’s specialty ingredients business provides microbial control solutions for Professional Hygiene and Personal Care products and offers the custom development and manufacturing of specialty chemicals and composites to support the electronics, aerospace, food and agrochemical industries
Click here to read full press release/ article | Ref: Lonza | Image: 24 News Update Blog
The post Lonza to Divest Specialty Ingredients Business to Bain Capital and Cinven for $4.7B first appeared on PharmaShots.
